ArticleCancer research communications2026
Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control.
Patrick A A Weber et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.